Published in J Infect on April 18, 2010
Assessing the overall quality of health care in persons living with HIV in an urban environment. AIDS Patient Care STDS (2014) 0.81
Predictive factors of herpes zoster HIV-infected patients: another adverse effect of crack cocaine. PLoS One (2013) 0.77
Apropos "Seroprevalence of common vaccine-preventable viral infections in HIV-positive adults". J Infect (2010) 0.75
Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand. BMC Infect Dis (2016) 0.75
Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II. Infect Dis Ther (2017) 0.75
Soil transmitted helminth infections are not associated with compromised antibody responses to previously administered measles and tetanus vaccines among HIV-1 infected, ART naïve Kenyan adults. Parasite Epidemiol Control (2017) 0.75
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med (2008) 5.54
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med (2002) 4.89
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA (2011) 3.08
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04
Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. BMJ (2012) 2.66
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr (2010) 2.59
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet (2011) 2.50
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Evaluation of care and surveillance of cardiovascular disease: can we trust medico-administrative hospital data? Can J Cardiol (2012) 2.10
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction. JAMA (2010) 2.04
Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis (2011) 2.03
Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med (2007) 1.94
Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc (2010) 1.87
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis (2012) 1.76
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ (2012) 1.71
Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother (2007) 1.70
Cooperation between the default mode network and the frontal-parietal network in the production of an internal train of thought. Brain Res (2011) 1.61
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS (2003) 1.60
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol (2012) 1.55
The role of cerebral hyperperfusion in postoperative neurologic dysfunction after left ventricular assist device implantation for end-stage heart failure. J Thorac Cardiovasc Surg (2009) 1.52
Integrated proteomic and transcriptomic profiling of mouse lung development and Nmyc target genes. Mol Syst Biol (2007) 1.50
Achieving compliance with the European Working Time Directive in a large teaching hospital: a strategic approach. Clin Med (2004) 1.49
Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens. Int J Tuberc Lung Dis (2011) 1.46
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS (2015) 1.44
The changing pattern of bronchoscopy in an HIV-infected population. Chest (2002) 1.42
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther (2008) 1.41
Travel-associated acquisition of hepatitis C virus infection in patients receiving haemodialysis. Nephrol Dial Transplant (2007) 1.41
Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection. AIDS (2003) 1.41
Iatrogenic effects of group treatment for antisocial youths. J Consult Clin Psychol (2005) 1.41
Rabies virus in a dog imported to the UK from Sri Lanka. Vet Rec (2008) 1.40
Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sex Transm Infect (2010) 1.40
Suicidal ideation in UK HIV clinic attenders. AIDS (2008) 1.31
Data linkage reduces loss to follow-up in an observational HIV cohort study. J Clin Epidemiol (2010) 1.26
Anterior cervical decompression and fusion with plate fixation as an outpatient procedure. Spine J (2005) 1.25
Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS (2008) 1.23
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 1.23
Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther (2008) 1.21
Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 1.20
Long-term trends in adherence to antiretroviral therapy from start of HAART. AIDS (2010) 1.17
Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother (2007) 1.16
Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis (2012) 1.15
Comparative evaluation of the ExaVir Load version 3 reverse transcriptase assay for measurement of human immunodeficiency virus type 1 plasma load. J Clin Microbiol (2009) 1.15
High-quality gene assembly directly from unpurified mixtures of microarray-synthesized oligonucleotides. Nucleic Acids Res (2010) 1.14
Evidence for onward transmission of HIV-1 non-B subtype strains in the United Kingdom. J Acquir Immune Defic Syndr (2006) 1.14
Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. AIDS (2008) 1.11
Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother (2009) 1.11
The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008. PLoS One (2011) 1.09
Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention? AIDS (2009) 1.09
Mice that overexpress human heat shock protein 27 have increased renal injury following ischemia reperfusion. Kidney Int (2008) 1.08
HIV phylogenetics. BMJ (2007) 1.07
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS (2007) 1.07
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS (2008) 1.07
Impact of UK academic foundation programmes on aspirations to pursue a career in academia. Med Educ (2010) 1.07
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica (2009) 1.07
Caring for women living with HIV: gaps in the evidence. J Int AIDS Soc (2013) 1.07
Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J Clin Microbiol (2013) 1.06
Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS (2010) 1.05
Adherence to antiretroviral treatment in patients with HIV in the UK: a study of complexity. AIDS Care (2008) 1.05
Health Policy and Systems Research in Twelve Eastern Mediterranean Countries: a stocktaking of production and gaps (2000-2008). Health Res Policy Syst (2011) 1.04
What factors are associated with patient self-reported health status among HIV outpatients? A multi-centre UK study of biomedical and psychosocial factors. AIDS Care (2012) 1.04
Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy. J Bone Miner Res (2013) 1.03
Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS (2014) 1.03
Herpes simplex virus type 2 (HSV-2) seroprevalence at the time of HIV-1 diagnosis and seroincidence after HIV-1 diagnosis in an ethnically diverse cohort of HIV-1-infected persons. Sex Transm Dis (2006) 1.03
Vital Signs: Estimated Effects of a Coordinated Approach for Action to Reduce Antibiotic-Resistant Infections in Health Care Facilities - United States. MMWR Morb Mortal Wkly Rep (2015) 1.03
The temporalis pocket technique for cochlear implantation: an anatomic and clinical study. Otol Neurotol (2009) 1.03
Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors. PLoS One (2011) 1.02
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS (2008) 1.02
Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. Nephrol Dial Transplant (2012) 1.02
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother (2011) 1.01
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS (2010) 1.01
Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study. BMC Fam Pract (2010) 1.00
Seroprevalence of cytomegalovirus, Epstein Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study. PLoS One (2013) 1.00
Escaping the here and now: evidence for a role of the default mode network in perceptually decoupled thought. Neuroimage (2012) 0.99
Economic analysis of combined endoscopic and endobronchial ultrasound in the evaluation of patients with suspected non-small cell lung cancer. Lung Cancer (2009) 0.99
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr (2010) 0.99
Successive switching of antiretroviral therapy is associated with high psychological and physical burden. Int J STD AIDS (2007) 0.98
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med (2013) 0.98
Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis (2012) 0.98